Bao Pharma repurchases 137,300 H-shares, treasury stock climbs to 284,600

Bulletin Express07-07

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a next-day return showing an on-market repurchase of 137,300 H-shares on 7 July 2026.

• Transaction details: Shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 18.64 to HKD 19.19, for a volume-weighted average cost of HKD 18.94 per share. The aggregate consideration was HKD 2.60 million.

• Capital structure impact: The repurchase reduced issued share capital (excluding treasury shares) from 154.18 million to 154.04 million, a marginal decrease of 0.09%. Treasury shares doubled from 147,300 to 284,600, keeping total issued shares unchanged at 154.33 million.

• Mandate utilisation: The buy-back forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 15.43 million shares. Cumulative purchases under this mandate now stand at 284,600 shares, representing 0.18% of the company’s issued shares on the mandate date.

• Post-repurchase restrictions: In line with HKEX rules, Bao Pharma is subject to a moratorium on issuing new shares or selling treasury shares until 6 August 2026.

Executive Director Liu Yanjun confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122343240?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122343240","market":"us","top_or_hot":-1,"title":"Bao Pharma repurchases 137,300 H-shares, treasury stock climbs to 284,600","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a next-day return showing an on-market repurchase of 137,300 H-shares on 7 July 2026.</p>\n<p>• Transaction details: Shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 18.64 to HKD 19.19, for a volume-weighted average cost of HKD 18.94 per share. The aggregate consideration was HKD 2.60 million.</p>\n<p>• Capital structure impact: The repurchase reduced issued share capital (excluding treasury shares) from 154.18 million to 154.04 million, a marginal decrease of 0.09%. Treasury shares doubled from 147,300 to 284,600, keeping total issued shares unchanged at 154.33 million.</p>\n<p>• Mandate utilisation: The buy-back forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 15.43 million shares. Cumulative purchases under this mandate now stand at 284,600 shares, representing 0.18% of the company’s issued shares on the mandate date.</p>\n<p>• Post-repurchase restrictions: In line with HKEX rules, Bao Pharma is subject to a moratorium on issuing new shares or selling treasury shares until 6 August 2026.</p>\n<p>Executive Director Liu Yanjun confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma repurchases 137,300 H-shares, treasury stock climbs to 284,600</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma repurchases 137,300 H-shares, treasury stock climbs to 284,600\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-07 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a next-day return showing an on-market repurchase of 137,300 H-shares on 7 July 2026.</p>\n<p>• Transaction details: Shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 18.64 to HKD 19.19, for a volume-weighted average cost of HKD 18.94 per share. The aggregate consideration was HKD 2.60 million.</p>\n<p>• Capital structure impact: The repurchase reduced issued share capital (excluding treasury shares) from 154.18 million to 154.04 million, a marginal decrease of 0.09%. Treasury shares doubled from 147,300 to 284,600, keeping total issued shares unchanged at 154.33 million.</p>\n<p>• Mandate utilisation: The buy-back forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 15.43 million shares. Cumulative purchases under this mandate now stand at 284,600 shares, representing 0.18% of the company’s issued shares on the mandate date.</p>\n<p>• Post-repurchase restrictions: In line with HKEX rules, Bao Pharma is subject to a moratorium on issuing new shares or selling treasury shares until 6 August 2026.</p>\n<p>Executive Director Liu Yanjun confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1122343240","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122343240","pubTimestamp":1783422249,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a next-day return showing an on-market repurchase of 137,300 H-shares on 7 July 2026. • Transaction details: Shares were bought back on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝药业回购13.73万股H股库存股攀升至28.46万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a next-day return showing an on-market repurchase of 137,300 H-shares on 7 July 2026.\n• Transaction details: Shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 18.64 to HKD 19.19, for a volume-weighted average cost of HKD 18.94 per share. The aggregate consideration was HKD 2.60 million.\n• Capital structure impact: The repurchase reduced issued share capital (excluding treasury shares) from 154.18 million to 154.04 million, a marginal decrease of 0.09%. Treasury shares doubled from 147,300 to 284,600, keeping total issued shares unchanged at 154.33 million.\n• Mandate utilisation: The buy-back forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 15.43 million shares. Cumulative purchases under this mandate now stand at 284,600 shares, representing 0.18% of the company’s issued shares on the mandate date.\n• Post-repurchase restrictions: In line with HKEX rules, Bao Pharma is subject to a moratorium on issuing new shares or selling treasury shares until 6 August 2026.\nExecutive Director Liu Yanjun confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122343240","isCrawlerRequest":true}